Press Release: Vitality Biopharma Adopts New Name -- Malachite Innovations, Inc.
Press Release: Vitality Biopharma Adopts New Name -- Malachite Innovations, Inc.
Press Release: Vitality Biopharma Adopts New Name -- Malachite Innovations, Inc.
新闻稿：活力生物制药公司采用新名称--孔雀石创新公司
Vitality Biopharma Adopts New Name -- Malachite Innovations, Inc.
活力生物制药公司采用新名称--孔雀石创新公司。
New Corporate Name Reflects Company's Expanded Business Strategy, Corporate Restructuring, and Other Corporate Changes
新的公司名称反映了公司的扩展业务战略、公司重组和其他公司变化
CLEVELAND, Ohio, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. has changed its name to MALACHITE INNOVATIONS, INC. (OTC Mkts: MLCT) (pronounced "mal-a-kite") following a corporate restructuring intended to reflect the Company's expanded business strategy and corporate rebranding. The Company also announced other corporate changes in support of the Company's new strategic plan to create long-term sustainable value for its shareholders.
俄亥俄州克利夫兰，2021年10月12日(环球通讯社)--Vitality Biophma，Inc.更名为孔雀石创新公司。(场外交易代码：MLCT)(发音为“mal-a-kite”)，此前该公司进行了旨在反映公司扩大业务战略和公司品牌重塑的公司重组。该公司还宣布了其他公司变动，以支持公司为股东创造长期可持续价值的新战略计划。
Expanded Strategy
扩展战略
Malachite has charted a dual, interconnected strategy to improve the health and wellness of people and our planet through the formation and operation of two new business units, Graphium Biosciences, Inc. and Daedalus Ecosciences, Inc.
孔雀石公司制定了一项双重的、相互关联的战略，通过组建和运营两个新的业务部门--石墨生物科学公司和Daedalus生态科学公司--来改善人类和我们这个星球的健康和福祉。
Graphium Biosciences, the newly-formed operating subsidiary dedicated to improving the health and wellness of people, will advance our broad portfolio of over 100 novel cannabinoid-glycoside compounds created using our proprietary enzymatic bioprocessing technologies to develop safe and effective novel treatments for chronic and debilitating conditions, with an initial focus on inflammatory bowel disease. Effective September 30, 2021, all of the Company's drug development operations will be conducted through Graphium Biosciences.
致力于改善人们的健康和健康的新成立的运营子公司Graphium Biosciences将推进我们利用我们的专有酶生物处理技术创造的100多种新型大麻苷化合物的广泛产品组合，以开发针对慢性和衰弱疾病的安全有效的新疗法，最初的重点是炎症性肠道疾病。从2021年9月30日起，该公司的所有药物开发业务都将通过石墨生物科学公司进行。
Daedalus Ecosciences, the newly-formed operating subsidiary dedicated to improving the health and wellness of our planet, will seek to identify, invest in and reposition challenging environmental situations with a particular focus on technological innovations and eco-friendly solutions deployed in economically challenged communities. Effective September 30, 2021, all of the Company's environmental operations will be conducted through Daedalus Ecosciences.
Daedalus Ecosciences是一家新成立的运营子公司，致力于改善我们地球的健康和福祉，该公司将寻求识别、投资和重新定位具有挑战性的环境状况，特别关注在经济困难社区部署的技术创新和生态友好型解决方案。从2021年9月30日起，该公司的所有环境业务都将通过Daedalus生态科学公司进行。
Malachite will serve as the publicly-traded holding company and oversee all strategic, financial and operational aspects of its wholly-owned subsidiaries, Graphium Biosciences and Daedalus Ecosciences.
孔雀石公司将作为上市控股公司，监督其全资子公司Graphium Biosciences和Daedalus Ecosciences的所有战略、财务和运营方面。
Corporate Rebranding
企业品牌重塑
The Company's Board of Directors approved this name change in furtherance of our expanded strategy and to mark the rebirth of our Company as we transition to the value creation phase of our strategic plan after successfully executing our multi-year restructuring plan. Our new corporate name is derived from the malachite butterfly whose brilliant green wings and rebirth imagery symbolize powerful transformation, good fortune and future prosperity for those who innovate and change.
公司董事会批准了这一更名，以进一步推进我们的扩展战略，并标志着我们的公司在成功执行多年重组计划后，过渡到我们战略计划的价值创造阶段，从而标志着我们公司的重生。我们的新公司名称来源于孔雀石蝴蝶，它灿烂的绿色翅膀和重生的意象象征着那些创新和变革的人强大的转型、好运和未来的繁荣。
Effective October 12, 2021, FINRA has approved a change in the Company's trading symbol from VBIO to MLCT.
自2021年10月12日起，FINRA已批准将公司的交易代码从VBIO改为MLCT。
In connection with this name change, Malachite has launched a new website to provide our shareholders and the financial community with detailed information about our corporate philosophy, innovations, team and investor resources. Our new website can be found at: www.malachiteinnovations.com.
与此次更名相关的是，孔雀石推出了一个新的网站，为我们的股东和金融界提供有关我们的公司理念、创新、团队和投资者资源的详细信息。我们的新网站是：www.malachiteInnovations.com。
Other Corporate Changes
其他公司变更
Effective September 30, 2021, our Board of Directors approved a change in the Company's fiscal year from the twelve months ending March 31 to the twelve months ending December 31. The Company will file a transition report on Form 10-K for the period ended December 31, 2021. The synchronization of the Company's fiscal year with the calendar year is intended to better align the Company's financial reporting schedule with other publicly-traded companies.
从2021年9月30日起，我们的董事会批准将公司的会计年度从截至3月31日的12个月改为截至12月31日的12个月。该公司将提交截至2021年12月31日的10-K表格过渡报告。本公司会计年度与历年同步的目的是为了更好地使本公司的财务报告时间表与其他上市公司保持一致。
We also have moved our corporate headquarters from Los Angeles, California to Cleveland, Ohio where many of the Company's directors, officers and advisors are located. Additionally, our new corporate headquarters is intended to provide the Company with an attractive physical location to expand our organization in support of the anticipated growth of our Graphium Biosciences and Daedalus Ecosciences operations.
我们还将公司总部从加利福尼亚州的洛杉矶迁至俄亥俄州的克利夫兰，公司的许多董事、高级管理人员和顾问都在那里。此外，我们的新公司总部旨在为公司提供一个有吸引力的地理位置，以扩大我们的组织，以支持我们的石墨生物科学公司和Daedalus生态科学公司业务的预期增长。
About Malachite Innovations, Inc.
孔雀石创新公司简介
Headquartered in Cleveland, Ohio, Malachite Innovations, Inc. is an innovative socially-conscious company dedicated to improving the health and wellness of people and our planet. Malachite deploys this dual, interconnected strategy through two wholly-owned operating subsidiaries. Graphium Biosciences, our operating subsidiary dedicated to improving the health and wellness of people, seeks to advance our broad portfolio of over 100 novel cannabinoid-glycoside compounds created using our proprietary enzymatic bioprocessing technologies to develop safe and effective novel treatments for chronic and debilitating conditions, with an initial focus on inflammatory bowel disease. Daedalus Ecosciences, our operating unit dedicated to improving the health and wellness of our planet, seeks to identify, invest in and reposition challenging environmental situations with a particular focus on technological innovations and eco-friendly solutions deployed in economically challenged communities.
孔雀创新公司总部设在俄亥俄州克利夫兰，是一家具有社会意识的创新公司，致力于改善人们和地球的健康和福祉。孔雀石通过两家全资运营的子公司部署这一双重的、相互关联的战略。Graphium Biosciences是我们的运营子公司，致力于改善人们的健康和健康，该公司致力于推进我们利用我们专有的酶生物处理技术创造的100多种新型大麻苷化合物的广泛产品组合，以开发针对慢性和衰弱疾病的安全有效的新疗法，最初的重点是炎症性肠道疾病。Daedalus Ecosciences是我们致力于改善地球健康和福祉的运营部门，致力于识别、投资和重新定位具有挑战性的环境状况，特别关注在经济困难社区部署的技术创新和生态友好型解决方案。
Notice Regarding Forward-Looking Statements
关于前瞻性陈述的通知
This press release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Although we believe that these statements are based on reasonable assumptions, they are subject to numerous factors that could cause actual outcomes and results to be materially different from those indicated in such statements. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, timing of clinical trials and product development, business strategy and new lines of business. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
本新闻稿包含“前瞻性陈述”，该术语在修订后的1933年“证券法”第27(A)节和修订后的1934年“证券交易法”第21(E)节中有定义。本新闻稿中非纯粹历史性的陈述是前瞻性陈述，包括任何有关对未来的信念、计划、期望或意图的陈述。尽管我们认为这些陈述是基于合理的假设，但它们受到许多因素的影响，这些因素可能导致实际结果和结果与此类陈述中显示的结果大不相同。这些因素包括与新项目和开发阶段公司相关的固有不确定性、临床试验和产品开发的时间安排、业务战略和新业务线。这些前瞻性陈述是截至本新闻稿发布之日作出的，我们没有义务更新前瞻性陈述，也没有义务更新实际结果可能与前瞻性陈述中预测的结果不同的原因。尽管我们相信本新闻稿中包含的任何信念、计划、预期和意图都是合理的，但不能保证任何此类信念、计划、预期或意图将被证明是准确的。投资者应查阅此处列出的所有信息，还应参考我们最近一个会计年度的Form 10-K年度报告、Form 10-Q季度报告以及不定期提交给证券交易委员会的其他定期报告中概述的风险因素披露。
Malachite Innovations, Inc.
孔雀石创新公司
Investor Relations
投资者关系
P: +1 (216) 304-6556
P: +1 (216) 304-6556
E: ir@malachiteinnovations.com
电子邮箱：ir@malachiteInnovation ations.com
W: www.malachiteinnovations.com
W：www.malachiteInnovations.com
(END) Dow Jones Newswires
(完)道琼通讯社
October 12, 2021 09:06 ET (13:06 GMT)
2021年10月12日东部时间09：06(格林尼治标准时间13：06)